Appeals Court Revives Teva's $176.5M Migraine Drug Patent Lawsuit Against Eli Lilly
Summary
A U.S. appeals court has revived Teva Pharmaceutical's patent infringement lawsuit against Eli Lilly concerning their competing migraine drugs, Emgality and Ajovy. This decision reverses a lower court's ruling that had overturned a prior $176.5 million jury verdict against Lilly. The case, which involves Lilly's Emgality (generating over $870 million in 2024 revenue), now returns to Massachusetts federal court. This development reintroduces legal uncertainty and potential financial liability for a key product, requiring traders to reassess the ongoing legal risks for Eli Lilly. Investors should monitor the renewed court proceedings for further developments.
At the time of this announcement, LLY was trading at $912.29 on NYSE in the Life Sciences sector, with a market capitalization of approximately $861.9B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.